Analysts Issue Forecasts for Oncternal Therapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:ONCT)

Oncternal Therapeutics, Inc. (NASDAQ:ONCTFree Report) – HC Wainwright issued their Q1 2025 EPS estimates for Oncternal Therapeutics in a research note issued on Monday, May 13th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings per share of ($2.42) for the quarter. HC Wainwright currently has a “Buy” rating and a $19.00 price target on the stock. The consensus estimate for Oncternal Therapeutics’ current full-year earnings is ($10.67) per share. HC Wainwright also issued estimates for Oncternal Therapeutics’ Q2 2025 earnings at ($2.19) EPS, Q3 2025 earnings at ($2.00) EPS, Q4 2025 earnings at ($2.05) EPS and FY2025 earnings at ($8.59) EPS.

Separately, started coverage on Oncternal Therapeutics in a research report on Saturday. They issued a “hold” rating for the company.

Get Our Latest Analysis on ONCT

Oncternal Therapeutics Price Performance

NASDAQ:ONCT opened at $8.70 on Tuesday. The firm has a market capitalization of $25.75 million, a price-to-earnings ratio of -0.71 and a beta of 1.28. The business has a 50 day simple moving average of $8.68 and a 200-day simple moving average of $8.44. Oncternal Therapeutics has a 1 year low of $5.57 and a 1 year high of $13.14.

Oncternal Therapeutics (NASDAQ:ONCTGet Free Report) last announced its earnings results on Thursday, May 9th. The company reported ($2.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.88) by $0.05. Oncternal Therapeutics had a negative net margin of 3,160.73% and a negative return on equity of 107.67%. The firm had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $0.18 million. During the same period in the prior year, the company earned ($4.00) EPS.

Insider Activity

In other Oncternal Therapeutics news, Director Robert James Wills purchased 3,086 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The stock was purchased at an average cost of $8.96 per share, with a total value of $27,650.56. Following the purchase, the director now owns 10,000 shares of the company’s stock, valued at $89,600. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders have acquired 10,714 shares of company stock valued at $92,736. 8.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Oncternal Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ONCT. Richmond Brothers Inc. grew its position in shares of Oncternal Therapeutics by 69.8% during the 3rd quarter. Richmond Brothers Inc. now owns 494,042 shares of the company’s stock worth $148,000 after buying an additional 203,010 shares in the last quarter. Quantum Private Wealth LLC bought a new position in Oncternal Therapeutics during the 1st quarter worth about $250,000. Finally, Pasadena Private Wealth LLC increased its position in Oncternal Therapeutics by 79.4% during the 4th quarter. Pasadena Private Wealth LLC now owns 500,000 shares of the company’s stock valued at $268,000 after purchasing an additional 221,250 shares during the period. Institutional investors own 16.05% of the company’s stock.

About Oncternal Therapeutics

(Get Free Report)

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.

See Also

Earnings History and Estimates for Oncternal Therapeutics (NASDAQ:ONCT)

Receive News & Ratings for Oncternal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncternal Therapeutics and related companies with's FREE daily email newsletter.